193. プラダー・ウィリ症候群 Prader-Willi syndrome Clinical trials / Disease details

臨床試験数 : 113 / 薬物数 : 111 - (DrugBank : 26) / 標的遺伝子数 : 48 - 標的パスウェイ数 : 102

diseases per page:

Showing 1 to 10 of 113 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05701774 (ClinicalTrials.gov)	January 31, 2023	18/1/2023	Open-Label Extension Study of DCCR in Patients With Prader-Willi Syndrome	An Open-Label Study of DCCR (Diazoxide Choline) Extended-Release Tablets in Patients With Prader-Wil ...	Prader-Willi Syndrome	Drug: DCCR	Soleno Therapeutics, Inc.	NULL	Not yet recruiting	4 Years	N/A	All	83	Phase 3	NULL
2	NCT05387798 (ClinicalTrials.gov)	January 2023	17/5/2022	A Phase 3 Extension Study of RAD011 (Cannabidiol Oral Solution) in Patients With Prader-Willi Syndro ...	A Phase 3, Open-label Extension Study to Assess the Safety, Tolerability, and Efficacy of RAD011 (Ca ...	Prader-Willi Syndrome	Drug: RAD011	Radius Pharmaceuticals, Inc.	NULL	Withdrawn	8 Years	65 Years	All	0	Phase 3	NULL
3	NCT05504395 (ClinicalTrials.gov)	November 14, 2022	4/8/2022	A Pharmacokinetic and Safety Study of CSTI-500 in Subjects With Prader-Willi Syndrome	A Phase 1, Single Center, Open Label, Single Dose, Pharmacokinetic and Safety Study of CSTI-500 in S ...	Prader-Willi Syndrome	Drug: CSTI-500	ConSynance Therapeutics	NULL	Recruiting	13 Years	50 Years	All	14	Phase 1	United States
4	NCT05541003 (ClinicalTrials.gov)	November 2022	1/9/2022	Understanding the Role of Gut Microbiota in Hyperphagia in Prader-Willi Syndrome	Understanding the Role of Gut Microbiota in Hyperphagia in Prader-Willi Syndrome	Prader-Willi Syndrome;Obesity	Drug: NBT-NM108	Rutgers, The State University of New Jersey	NULL	Recruiting	18 Years	35 Years	All	10	Phase 2	United States
5	NCT05322096 (ClinicalTrials.gov)	September 22, 2022	25/3/2022	Study to Evaluate Efficacy, Safety, and Tolerability of RGH-706 in Prader-Willi Syndrome	A Randomized, Double-blind, Placebo-controlled, Multi-center, 2-part, Phase 2 Study to Evaluate Effi ...	Prader-Willi Syndrome	Drug: RGH-706;Drug: Placebo	Gedeon Richter Plc.	NULL	Recruiting	17 Years	N/A	All	176	Phase 2	United States;Czechia;France;Italy;Spain
6	NCT05098509 (ClinicalTrials.gov)	April 13, 2022	22/9/2021	A Phase 2/3 Study of RAD011 (Cannabidiol Oral Solution) for the Treatment of Patients With Prader-Wi ...	A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study of RAD011 (Cannabidiol Oral Solution ...	Prader-Willi Syndrome	Drug: RAD011;Drug: Placebo	Radius Pharmaceuticals, Inc.	NULL	Terminated	8 Years	65 Years	All	7	Phase 2/Phase 3	United States
7	NCT05298085 (ClinicalTrials.gov)	April 5, 2022	17/3/2022	Effect of Intranasal Oxytocin on Dysphagia in Children and Adolescents With Prader-Willi Syndrome	Effect of Intranasal Oxytocin on Dysphagia Related to Oropharyngo-oesophageal Dysmotility in Childre ...	Prader-Willi Syndrome	Drug: Oxytocin nasal spray;Drug: Placebo	University Hospital, Toulouse	NULL	Active, not recruiting	2 Years	17 Years	All	25	Phase 2/Phase 3	France
8	EUCTR2021-000127-12-SE (EUCTR)	03/01/2022	08/11/2021	A 16-week phase 2b, double-blind, placebo-controlled, Multi center, dose finding safety and efficacy ...	A Phase 2b, Double-blind, Randomized, Placebo-controlled, Multi center, 16-week Dose finding, Safety ...	Prader-Willi Syndrome MedDRA version: 20.0;Level: PT;Classification code 10036476;Term: Prader-Willi ...	Product Name: Tesomet INN or Proposed INN: Tesofensine Other descriptive name: TESOFENSINE CITRATE INN o ...	Saniona A/S	NULL	Not Recruiting			Female: yes Male: yes	120	Phase 2	France;United States;Spain;Belgium;Ireland;Australia;United Kingdom;New Zealand;Italy;Sweden
9	NCT05198362 (ClinicalTrials.gov)	December 28, 2021	5/1/2022	Study of Tesomet With Open-label Extension in Subjects With Prader-Willi Syndrome	A Phase 2b, Double-blind, Randomized, Placebo-controlled, Multi-center, 16-week Dose Finding, Safety ...	Prader-Willi Syndrome	Other: Placebo;Drug: Tesomet	Saniona	NULL	Withdrawn	13 Years	65 Years	All	0	Phase 2	United States
10	NCT05032326 (ClinicalTrials.gov)	September 7, 2021	24/6/2021	Long-term Interventional Follow-up Study of Children With Prader-Willi SyndromeIncluded in the OTBB3 ...	Long-term Interventional Follow-up Study up to 4 Years of Age of Children With Prader-Willi Syndrome ...	Prader-Willi Syndrome	Drug: Follow-up study of the treated cohort;Other: Follow-up study of the untreated cohort	University Hospital, Toulouse	NULL	Recruiting	12 Months	36 Months	All	80	Phase 3	France

First Previous1 2 3 4 5…12Next Last